Chris Buyse, Chief Financial Officer and Board Member of ThromboGenics NV, will resign effective June 30, 2014. As of July 1, 2014 Luc Philips, former CFO of KBC group and Board Member of ThromboGenics since its IPO, will take on the role of interim-CFO until the Company completes an international search for a new permanent CFO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 EUR | -.--% | -.--% | -88.89% |
Apr. 12 | Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 06 | Oxurion Raises Additional Funds from Convertible Bonds Issue | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-88.89% | 1.33M | |
+43.34% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- OXUR Stock
- News Oxurion NV
- ThromboGenics NV Announces Executive Changes, Effect from June 30, 2014